T-cell receptor recognizing Mucin 1 and Survivin peptide-MHC complexes (MUC1/Survivin TCR)

The T-cell receptors (TCRs) recognizing Mucin 1 (MUC1) and Survivin (BIRC5) peptide-MHC complexes are specialized immune receptors used in advanced cancer immunotherapy [1, 2]. MUC1 is a transmembrane glycoprotein frequently overexpressed and aberrantly glycosylated in epithelial malignancies, such as breast, lung, and pancreatic cancers [1]. Survivin is an inhibitor of apoptosis protein (IAP) that is highly expressed in most human tumors but nearly absent in healthy adult tissues, making it an ideal target for cytotoxic T cells [2]. These TCRs, whether naturally occurring or engineered into T cells (TCR-T therapy), specifically bind to peptides derived from MUC1 and Survivin when presented by Major Histocompatibility Complex (MHC) molecules [3]. CD8+ T cells typically recognize MHC Class I-restricted peptides to induce direct apoptosis, while CD4+ T cells recognize MHC Class II-restricted peptides to coordinate the broader immune response [4]. By targeting both MUC1 and Survivin simultaneously, these therapies aim to overcome tumor heterogeneity and reduce the risk of immune escape through antigen loss [5]. Clinical applications include the development of multi-antigen peptide vaccines and TCR-engineered T-cell products designed to treat a wide range of solid tumors [3, 5]. Monitoring for HLA compatibility and target antigen expression is essential for patient selection and treatment efficacy [4]. Safety considerations primarily involve managing potential on-target off-tumor toxicities and systemic inflammatory responses like cytokine release syndrome [3].

Other names

MUC1-specific TCRSurvivin-specific TCRBIRC5-specific TCRMUC1/BIRC5 dual-targeting T-cell receptorCD4+/CD8+ T-cell receptors recognizing MUC1 and survivin

Recognition of specific MUC1 and Survivin peptides presented by MHC molecules on tumor cells, leading to T-cell activation and targeted cell lysis.